Hebei Changshan Biochemical Pharmaceutical announced that its product Dalteparin Sodium Injection has been selected for the 12th round of national centralized drug procurement. The selected specifications are 0.2 ml: 5000 IU and 0.3 ml: 7500 IU, with indications including acute deep vein thrombosis and anticoagulation for hemodialysis. The product achieved sales revenue of 119.94 million yuan in 2025, accounting for 13.71 percent of the company's total revenue for the year. The procurement cycle runs from the implementation date of the selection results until December 31, 2029. The company stated that if procurement contracts are subsequently signed and executed, it will help promote product sales, but there remains uncertainty regarding contract signing and the impact on future performance.
Hebei Changshan Biochem PharmaProduct selected for national procurement, likely boosting sales.